ACXP News and Press, Acurx Pharmaceuticals Inc. From 09/16/22

NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- FMW Media's New to The Street / Newsmax TV announces the broadcasting line-up of its national syndicated 1-hour TV show this Sunday, September 18, 2022, airing time 10-11 AM ET. New to The Street's 386th TV episode l...

Ridinilazole failed to meet the endpoint of superiority over vancomycin in phase 3 trials. Summit Therapeutics has a preclinical antibiotic for Enterobacteriaceae, an infection where there is a clear need for novel therapeutics. Antibiotics are an extremely difficult segment of th...

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2022 Earnings Conference Call August 16, 2022, 08:30 AM ET Company Participants Robert Shawah - CFO David Luci - CEO Conference Call Participants Jim Molloy - Alliance Global Partners Presentation Operat...

Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q2 GAAP EPS of -$0.26. The company ended the second quarter on Jun 30, 2022, with cash totaling $9.1M compared to $13.1M as of Dec. 31, 2021. For further details see: Acurx Pharmaceuticals GAAP EPS of -$0.26 ...

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Aug. 15, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical s...

Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , Aug. 4, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" ...

Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America PR Newswire New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from ...

Clinical-stage biopharmaceutical company, Acurx Pharmaceuticals ( NASDAQ: ACXP ) entered agreement with a single healthcare-focused U.S. institutional investor and certain executives of the company for the purchase and sale of an aggregate of 1.29M shares (...

Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering PR Newswire STATEN ISLAND, N.Y. , July 25, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical-stage biopharmaceutical compa...

Seres' $100 million share placement with strategic partners, including Nestle, helps stabilize the share price. The C. difficile market - how big is it? Who can compete with the Seres/Nestle (Aimmune Therapeutics) global rollout for C. difficile recurrence? Seres has had two share...